UNITY Biotechnology Reports New Recruitment Awards | Aici

Company Unity Biotechnology, Inc.

SOUTH SAN FRANCISCO, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ: UBX), a biotechnology company developing treatments to reduce, stop, or reverse the diseases of aging, today announced that from January 3, 2023, until January 17, 2023, the Compensation Committee of the Board of Directors (“Board ”) granted the new employee a stock-based award consisting of an aggregate of 900 shares of UNITY common stock, including options to purchase an aggregate of 900 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Incentive Plan, as amended, which was approved by the Board in March 2020 to provide incentives to newly hired employees as a tangible incentive to begin employment with UNITY in accordance. per Nasdaq Stock Market Rule 5635(c)(4).

UNITY is developing a new class of drugs to slow, stop or reverse the diseases of aging. UNITY is focused on creating drugs that will selectively remove or alter stem cells and thus provide a revolutionary benefit in age-related eye diseases and neurological diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media contact
Wake up the Canale
Jason Spark

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *